JOINT RESEARCH
- HOME
- Joint research and development
About joint research and development:
Solving problems with the SENTAN platform: Should you be interested in highlighting and increasing the potential of your chemicals, please contact us.
We can assist you with
- abandoned development due to strong side effects
- improving the dispersibility of poorly soluble components
- nanoparticle formulations that are too expensive, difficult to scale up, or do not have an uniform particle size
- your consideration of a microparticle formulation, by discussing with you the formulation design, controlling the sustained-release rate, the transition to GMP system, and consistent performance from the initial study to the GMP production.
Drug-encapsulated PLGA nanoparticulate feasibility study basic set
1. Examination of optimal conditions for PLGA nanoparticle formation of compounds
2. Report the results of physical property evaluation:
3. Delivery of PLGA nanoparticles manufactured under optimal conditions
4. Submission of the final report
2. Report the results of physical property evaluation:
drug loading and release rate, particle size distribution, powder X-ray diffraction, transmission electron microscopy
3. Delivery of PLGA nanoparticles manufactured under optimal conditions
4. Submission of the final report
Optional (added to core set):
Dissolution rate, AUC, zeta potential, DSC thermal analysis, blood concentration measurement
■ Items to be prepared by the customer at the time of contract
［ Compound, quantitative measurement methods, HPLC / GC column; ］
■ Compounds that are compatible with our nanotechnology:
［ fat-soluble and poorly soluble compounds ］
Long-term sustained release injection formulation Microparticulation feasibility study basic set:
1. Impact assessment of polymer species
2. Examination of impact assessment of drug preparation rate
3. Examination of the final product
Contents of examination: Preparation of formulation, evaluation of physical properties (measurement of particle size and content), evaluation of release
4. Submission of the final report
Optional (added to core set):
Blood drug concentration measurement:
■ Items to be prepared by the customer at the time of contract
［ Compound, quantitative measurement methods, HPLC / GC column; ］
■ Features
・ It is possible to provide a sustained-release function (for one to three months)
・ Consider scale-up and GMP manufacturing possible in collaboration with domestic CMO companies